Day: April 13, 2022

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic...

Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle Cell Lymphoma

Discontinued enrollment of Phase 1/2 trial of ONCT-216 in Ewing sarcomaResources will be primarily reallocated to our zilovertamab global registrational...

Fraser Health signs for MEDITECH Expanse to support 32 facilities across British Columbia—organization to leverage mobile technology and advanced clinical functionality to enhance care

WESTWOOD, Mass.--(BUSINESS WIRE)--Fraser Health (Surrey, B.C.) has selected MEDITECH Expanse to transform care and promote better health outcomes for the...

error: Content is protected !!